iTeos announces current business figures and plans for clinical development in 2023
– In 2023, both the anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and the adenosine A2A receptor antagonist inupadenant will make significant advances – Eleven planned or ongoing clinical trials across three pipeline …